Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Anthropic IPO Marketing Expected to Start in Mid-October 
Add as a preferred source on Google
DUBLIN, Ireland and TREVOSE, Pa., Feb. 28, 2018 -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Monday, March 12 at 8:30 a.m. ET to discuss the Company’s fourth quarter and year-end 2017 financial results and provide a corporate update. The conference call will follow the anticipated release of the Company’s financial results earlier that day.
Event Details
Strongbridge will host a conference call on Monday, March 12 at 8:30 a.m. ET. To access the live call, dial 844-285-7153 (domestic) or 478-219-0180 (international) with conference ID 6497969. The conference call will also be audio webcast from the Company’s website at www.strongbridgebio.com under the “Investor/Webcasts and Presentations” section. A replay of the call will be made available for one week following the conference call. To hear a replay of the call, dial 855-859-2056 (domestic) or 404-537-3406 (international) with conference ID 6497969.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]
Investor Relations
United States:
The Trout Group
Marcy Nanus
+1 646-378-2927
[email protected]
Europe:
First House
Mitra Hagen Negård
+47 21 04 62 19
[email protected]
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
